Meeting
2014 ASCO Annual Meeting
Phase I trial of pegylated liposomal doxorubicin in combination with BIBF 1120 (nintedanib) in platinum-resistant ovarian cancer: Hoosier Oncology Group GYN10-149.
Authors
Maria Creselda deLeon
Indiana University School of Medicine, Indianapolis, IN
Maria Creselda deLeon , Alesha Arnold , Emma Caroline Rossi , Jamie Case , Cynthia Johnson , Yan Zeng , Daniela Matei
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT01485874
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 5541^)
DOI
10.1200/jco.2014.32.15_suppl.5541
Abstract #
5541^
Poster Bd #
323
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 1 study of the SYK inhibitor fostamatinib and weekly paclitaxel for recurrent platinum-resistant ovarian cancer.
First Author: Stephanie Gaillard
Poster
2021 ASCO Annual Meeting
Pembrolizumab in combination with bevacizumab and pegylated liposomal doxorubicin in patients with platinum-resistant epithelial ovarian cancer.
First Author: Judith Michels
Poster
2019 ASCO Annual Meeting
Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): An open label, four-arm, phase II study.
First Author: Kathleen N. Moore
Poster
2018 ASCO Annual Meeting
Phase I clinical trials evaluating olaparib in combination with radiotherapy (RT) and/or temozolomide (TMZ) in glioblastoma patients: Results of OPARATIC and PARADIGM phase I and early results of PARADIGM-2.
First Author: Anthony J. Chalmers